Could diabetes drugs also protect kidneys by fixing fat?

NCT ID NCT07309094

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looks at whether GLP-1 drugs, used for diabetes and weight loss, can improve kidney health in people with chronic kidney disease. Researchers will measure changes in fat around the kidneys and heart, as well as kidney function. The goal is to see if these drugs reduce harmful fat-related inflammation that worsens kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide) and SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin)
What this could lead to
If successful, this could show that GLP-1 drugs improve kidney health by reducing harmful fat around organs, pointing toward a better way to manage chronic kidney disease.
What could go wrong
This is an early-stage study with 250 people, so results may not apply to everyone. The drugs can cause side effects like nausea or stomach issues, and it's unclear if they will directly slow kidney damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vithas Valencia Consuelo

    RECRUITING

    Valencia, Valencia, 46007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.